Randomized Phase II Trial of Nintedanib, Afatinib and Sequential Combination in Castration-Resistant Prostate Cancer

201433 citationsJournal Article

Authors

Nintedanib and/or afatinib demonstrated limited anti-tumor activity in unselected advanced castration-resistant prostate cancer patients.

Good health and well-being

Published in: Future Oncology

Volume 10, Issue 2, pp. 219-231

Field-Weighted Citation Impact: 3.77